Literature DB >> 33922062

Mitochondrial ATP-Dependent Proteases-Biological Function and Potential Anti-Cancer Targets.

Yue Feng1,2, Kazem Nouri1, Aaron D Schimmer1,2.   

Abstract

Cells must eliminate excess or damaged proteins to maintain protein homeostasis. To ensure protein homeostasis in the cytoplasm, cells rely on the ubiquitin-proteasome system and autophagy. In the mitochondria, protein homeostasis is regulated by mitochondria proteases, including four core ATP-dependent proteases, m-AAA, i-AAA, LonP, and ClpXP, located in the mitochondrial membrane and matrix. This review will discuss the function of mitochondrial proteases, with a focus on ClpXP as a novel therapeutic target for the treatment of malignancy. ClpXP maintains the integrity of the mitochondrial respiratory chain and regulates metabolism by degrading damaged and misfolded mitochondrial proteins. Inhibiting ClpXP genetically or chemically impairs oxidative phosphorylation and is toxic to malignant cells with high ClpXP expression. Likewise, hyperactivating the protease leads to increased degradation of ClpXP substrates and kills cancer cells. Thus, targeting ClpXP through inhibition or hyperactivation may be novel approaches for patients with malignancy.

Entities:  

Keywords:  AML; ClpXP; cancer; mitochondria; protease

Year:  2021        PMID: 33922062     DOI: 10.3390/cancers13092020

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  174 in total

Review 1.  Mitonuclear communication in homeostasis and stress.

Authors:  Pedro M Quirós; Adrienne Mottis; Johan Auwerx
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03-09       Impact factor: 94.444

2.  Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Authors:  Varun V Prabhu; Neel S Madhukar; Coryandar Gilvary; C Leah B Kline; Sophie Oster; Wafik S El-Deiry; Olivier Elemento; Faye Doherty; Alexander VanEngelenburg; Jessica Durrant; Rohinton S Tarapore; Sean Deacon; Neil Charter; Jinkyu Jung; Deric M Park; Mark R Gilbert; Jessica Rusert; Robert Wechsler-Reya; Isabel Arrillaga-Romany; Tracy T Batchelor; Patrick Y Wen; Wolfgang Oster; Joshua E Allen
Journal:  Clin Cancer Res       Date:  2018-12-17       Impact factor: 12.531

3.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Authors:  Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

4.  Oxygen-sensitive mitochondrial accumulation of cystathionine β-synthase mediated by Lon protease.

Authors:  Huajian Teng; Bo Wu; Kexin Zhao; Guangdong Yang; Lingyun Wu; Rui Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

5.  Mitochondrial Lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor A (TFAM).

Authors:  Yuichi Matsushima; Yu-ichi Goto; Laurie S Kaguni
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-07       Impact factor: 11.205

6.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Authors:  Marko Skrtić; Shrivani Sriskanthadevan; Bozhena Jhas; Marinella Gebbia; Xiaoming Wang; Zezhou Wang; Rose Hurren; Yulia Jitkova; Marcela Gronda; Neil Maclean; Courteney K Lai; Yanina Eberhard; Justyna Bartoszko; Paul Spagnuolo; Angela C Rutledge; Alessandro Datti; Troy Ketela; Jason Moffat; Brian H Robinson; Jessie H Cameron; Jeffery Wrana; Connie J Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Keith Humphries; Corey Nislow; Guri Giaever; Aaron D Schimmer
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

7.  CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon protease.

Authors:  Kevin A Strauss; Robert N Jinks; Erik G Puffenberger; Sundararajan Venkatesh; Kamalendra Singh; Iteen Cheng; Natalie Mikita; Jayapalraja Thilagavathi; Jae Lee; Stefan Sarafianos; Abigail Benkert; Alanna Koehler; Anni Zhu; Victoria Trovillion; Madeleine McGlincy; Thierry Morlet; Matthew Deardorff; A Micheil Innes; Chitra Prasad; Albert E Chudley; Irene Nga Wing Lee; Carolyn K Suzuki
Journal:  Am J Hum Genet       Date:  2015-01-08       Impact factor: 11.025

8.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

Review 9.  Mitochondria Targeting as an Effective Strategy for Cancer Therapy.

Authors:  Poorva Ghosh; Chantal Vidal; Sanchareeka Dey; Li Zhang
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

10.  PET Visualized Stimulation of the Vestibular Organ in Menière's Disease.

Authors:  Louise Devantier; Allan K Hansen; Jens-Jacob Mølby-Henriksen; Christian Bech Christensen; Tina Lildal; Michael Pedersen; Måns Magnusson; Per Borghammer; Therese Ovesen
Journal:  Front Neurol       Date:  2020-01-28       Impact factor: 4.003

View more
  1 in total

1.  Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor.

Authors:  Umar Hayat; Gary T Elliott; Anthony J Olszanski; Dario C Altieri
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.